HOME >> MEDICINE >> NEWS
More protests against abortion pill

Drug-induced abortion is now legal in the US, but there's a snag...

AFTER a ten-year fight, the "abortion pill" RU486 is finally available in the US. But the pill's supporters fear theirs may be a pyrrhic victory, because production of a second pill that has to be taken with RU486 is now under threat.

RU486 (mifepristone) was approved in Britain nine years ago as an alternative to surgical abortions in the first two months of pregnancy. But American anti-abortion campaigners fought bitterly against it. Now that the US Food and Drug Administration has approved mifepristone, attention has turned to misoprostol, a prostaglandin pill originally developed to treat gastric ulcers.

Supporters of RU486 told New Scientist that they fear anti-abortion campaigners will target misoprostol supply because, although it is officially produced to treat stomach ulcers, obstetricians use it to complete the abortion process started by RU486.

The Reverend Flip Benham, national director of Operation Rescue-one of the most powerful anti-abortion groups in the US-says any drug firms involved in pharmaceutical abortion will be targeted by his group. "If you're going to go ahead and make this pill, you better know that Christians in America do not want to buy pharmaceuticals from you."

RU486 blocks the action of the hormone progesterone, causing the lining of the uterus to break down. Taken two days later, misoprostol makes the uterus contract and the cervix dilate, helping to expel the embryo. But now it seems even the company that makes misoprostol is getting the jitters.

For years, obstetricians have used misoprostol to dilate the cervix during labour. But only when the FDA was about to approve its use with the abortion pill-following pressure from RU486 supporters-did the manufacturer, Pharmacia, send out a sternly worded letter warning against misoprostol's use during pregnancy. The drugs company insis
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
24-Oct-2000


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. New study in Nature demonstrates protection against cell death during heart attack
3. Vaccine against childhood pneumonia shows promise
4. Mayo Clinic discovers new pathway against pancreatic cancer
5. Orthodontists must brace against back pain
6. NYUS Duster cautions against FDA approval of race-based pharmaceutical
7. Female sex hormones play a vital role in defense against sexually transmitted diseases
8. New European cancer figures for 2004 major efforts needed against the big four killers
9. New highly active agents against sandfly fever
10. New mosquito control strategy proves successful against dengue fever
11. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: More protests against abortion pill

(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)...  PneumRx, Inc. ( www.pneumrx.com ), a leader in ... enrollment in their RENEW Study, nearly 3 months ahead ... IDE pivotal trial for the PneumRx RePneu Coil System, ... anticipated that the study, which began enrolling subjects in ... end of 2014 to enroll 315 patients.  Instead, enrollment ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
Cached News: